Jan Dürig

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Mattia D’Agostino, David A. Cairns, Juan José Lahuerta et al. · Journal of Clinical Oncology · 2022 · 371 citations · Full text

Tumor-derived exosomes modulate PD-L1 expression in monocytes

Franziska Haderk, Ralph Schulz, Murat Iskar et al. · Science Immunology · 2017 · 289 citations

Cancer Immunosurveillance, Exosomes, Pd-l1 Expression +12

miR-34a as part of the resistance network in chronic lymphocytic leukemia

Thorsten Zenz, Julia Mohr, Eric Eldering et al. · Blood · 2008 · 277 citations · Full text

Cellular origin and pathophysiology of chronic lymphocytic leukemia

Marc Seifert, Ludger Sellmann, Johannes Bloehdorn et al. · The Journal of Experimental Medicine · 2012 · 275 citations · Full text